Recurrent Urticaria in Children: Evaluation and Management
Start treatment immediately with a standard-dose second-generation H1-antihistamine (such as cetirizine, loratadine, or desloratadine) as first-line therapy, and classify the urticaria pattern to guide your diagnostic approach. 1, 2
Clinical Classification First
Determine whether this is:
- Acute urticaria (< 6 weeks): Most commonly viral in children, requires minimal workup
- Chronic urticaria (≥ 6 weeks continuous activity): Requires systematic evaluation
- Episodic/recurrent urticaria: Intermittent episodes with symptom-free intervals
The presentation in children mirrors adults, with chronic spontaneous urticaria (CSU) being the most common chronic pattern. 1, 3
Initial Evaluation
History - Focus on These Specific Elements:
- Duration and frequency of episodes (daily vs intermittent)
- Presence of angioedema (occurs in ~41% of pediatric cases) 4
- Physical triggers: Heat, cold, pressure, exercise, water contact (present in ~35% of cases) 4
- Individual lesion duration (< 24 hours suggests urticaria; > 24 hours suggests vasculitis)
- Associated symptoms: Fever, joint pain, bone pain (red flags for systemic disease)
- Aggravating factors: NSAIDs, aspirin, stress, overheating, tight clothing 1
Physical Examination:
- Document wheal characteristics (take photos if possible)
- Check for dermographism (stroke skin firmly)
- Look for signs of systemic disease or vasculitis
Diagnostic Testing Strategy
For Acute/Episodic Urticaria:
No routine laboratory testing is needed. 5 Only perform targeted allergy testing if history strongly suggests specific triggers (foods, drugs, insect stings). Most cases are viral and self-limited.
For Chronic Urticaria (≥ 6 weeks):
- Complete blood count with differential
- C-reactive protein or ESR
- Total IgE level (low levels suggest autoimmune CSU)
- IgG anti-thyroid peroxidase (anti-TPO) (elevated suggests autoimmune CSU)
- A high anti-TPO/total IgE ratio is the best surrogate marker for autoimmune CSU 2
Additional testing only if clinically indicated:
- Serum C4 if angioedema without wheals (screen for C1 esterase inhibitor deficiency) 1
- Skin biopsy if individual lesions last > 24 hours (rule out urticarial vasculitis) 1
- Stool examination only if specific parasitic exposure suspected 5
Do not perform routine extensive allergy testing, food panels, or autoimmune workups without clinical suspicion. 5 These yield low diagnostic value and lead to unnecessary interventions.
Treatment Algorithm
Step 1: Second-Generation H1-Antihistamines (First-Line)
Offer the child at least two different non-sedating antihistamines as options, as individual responses vary. 1
Approved options:
- Cetirizine (fastest onset, may be sedating at higher doses)
- Loratadine
- Desloratadine (longest half-life: 27 hours)
- Fexofenadine
- Levocetirizine
Dosing approach: 2
- Start at standard licensed dose once daily
- If inadequate control after 2-4 weeks (or earlier if symptoms intolerable), increase up to 4-fold the standard dose
- This off-license updosing is common practice and considered safe 1
Important pediatric considerations: 1
- Chlorphenamine (chlorpheniramine) is often chosen when antihistamines are necessary in pregnancy/young children due to long safety record
- Avoid hydroxyzine in pregnancy (specifically contraindicated)
- Adjust doses in renal/hepatic impairment
Step 2: Add Omalizumab (Second-Line)
If symptoms remain uncontrolled on up to 4-fold antihistamine dosing, add omalizumab. 2
Dosing: 2
- Start with 300 mg subcutaneously every 4 weeks
- Allow up to 6 months for response
- If insufficient response, consider updosing: shorten interval and/or increase dose
- Maximum: 600 mg every 2 weeks
- All children treated with omalizumab in recent studies responded 5
Step 3: Cyclosporine (Third-Line)
For patients unresponsive to high-dose omalizumab: 2
- Cyclosporine up to 5 mg/kg body weight
- Monitor blood pressure and renal function regularly
- Higher risk profile than omalizumab (hypertension, renal toxicity, hirsutism)
Adjunctive Measures:
For severe exacerbations: Short 3-day course of systemic glucocorticoids is effective 5
Avoid these medications: 1
- NSAIDs and aspirin (can worsen urticaria)
- ACE inhibitors (especially if angioedema present)
- Codeine (can trigger histamine release)
Symptomatic relief: 1
- Cooling lotions (calamine, 1% menthol in aqueous cream)
- Minimize overheating, stress, alcohol
Step-Down Strategy
Once complete control is achieved (defined as no symptoms), consider stepping down treatment cautiously: 2
- Wait at least 3 consecutive months of complete control before reducing antihistamine dose
- Reduce by no more than 1 tablet per month
- If breakthrough symptoms occur, return to last effective dose
- This approach assesses for spontaneous remission while minimizing treatment burden
Monitoring for Comorbidities
Screen for autoimmune conditions during follow-up, particularly: 6
- Autoimmune thyroid disease (most common association)
- Celiac disease
- Type 1 diabetes
- Vitiligo
These may develop during the course of chronic urticaria and can be identified through the diagnostic framework already in place.
Prognosis
Reassure families that prognosis is excellent: 1, 4
- 45-50% of pediatric chronic urticaria resolves within 3 years
- Most cases eventually remit spontaneously
- A cause is unlikely to be identified, but this does not affect treatment success
Common Pitfalls to Avoid
- Over-testing: Extensive allergy panels and autoimmune workups without clinical suspicion waste resources and cause anxiety 5
- Under-dosing antihistamines: Many children respond to 2-4x standard doses; don't rush to second-line therapy 2
- Using first-generation sedating antihistamines as monotherapy: These impair school performance and concentration 1
- Treating parasites without evidence: Only one case of Dientamoeba fragilis eradication showed benefit 5
- Premature step-down: Wait for sustained complete control before reducing treatment 2